INS and type 2 diabetes mellitus: In this context, with an abundance of positive results from different types of studies, yet with a reduced representation of countries from Central–Eastern Europe such as Romania and with reduced data from real-world trials, we aimed to evaluate the impact on CV risk factors, insulin resistance, and renal function of the treatment with GLP-1 RAs in patients with T2D.